Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives $131.86 Consensus Price Target from Analysts

Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) has been assigned an average recommendation of "Buy" from the seven ratings firms that are currently covering the company, MarketBeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $131.86.

Several research analysts have weighed in on the company. StockNews.com lowered Lantheus from a "buy" rating to a "hold" rating in a research report on Thursday, November 21st. The Goldman Sachs Group started coverage on shares of Lantheus in a research note on Wednesday, December 18th. They issued a "buy" rating and a $143.00 target price for the company. Truist Financial restated a "buy" rating and set a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $112.00 price objective on shares of Lantheus in a report on Tuesday.

Lantheus Price Performance

Lantheus stock traded down $1.26 during trading hours on Tuesday, hitting $93.39. The company had a trading volume of 334,773 shares, compared to its average volume of 798,579. The firm's fifty day moving average is $89.98 and its 200-day moving average is $99.78. Lantheus has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The firm has a market capitalization of $6.49 billion, a P/E ratio of 15.54 and a beta of 0.46.

Hedge Funds Weigh In On Lantheus

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Wilmington Savings Fund Society FSB acquired a new stake in Lantheus during the 3rd quarter valued at $25,000. Signaturefd LLC raised its holdings in shares of Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock valued at $35,000 after buying an additional 92 shares during the last quarter. UMB Bank n.a. raised its stake in shares of Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock worth $47,000 after acquiring an additional 126 shares during the last quarter. Kathleen S. Wright Associates Inc. bought a new stake in shares of Lantheus during the third quarter valued at approximately $51,000. Finally, GAMMA Investing LLC increased its holdings in shares of Lantheus by 45.5% in the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider's stock valued at $51,000 after purchasing an additional 146 shares in the last quarter. 99.06% of the stock is owned by institutional investors.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.